-
公开(公告)号：US20190231760A1
公开(公告)日：2019-08-01
申请号：US16289612
申请日：2019-02-28
Applicant: NOVARTIS AG
Inventor： Nicole BUSCHMANN , Robin Alec FAIRHURST , Pascal FURET , Diana GRAUS PORTA , Carolina HAEFLIGER , Bo HAN , Thomas KNOPFEL , Catherine LEBLANC , Lv LIAO , Robert MAH , Masato MURAKAMI , Pierre NIMSGERN , Michael PALMER , Dale PORTER , Sebastien RIPOCHE , Can WANG , Youzhen WANG , Andreas WEISS , Jing XIONG , Xianglin ZHAO
IPC: A61K31/4375 , A61P35/00 , A61K31/4545 , A61K31/496 , A61K31/55
Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof
-
公开(公告)号：US20240116900A1
公开(公告)日：2024-04-11
申请号：US18250466
申请日：2021-10-29
Applicant: NOVARTIS AG
Inventor： Simona COTESTA , Heng GE , Marc GERSPACHER , Catherine LEBLANC , Bo LIU , Edwige Liliane Jeanne LORTHIOIS , Rainer MACHAUER , Robert MAH , Tanja MEISTER , Christophe MURA , Pascal RIGOLLIER , Nadine SCHNEIDER , Stefan STUTZ , Andrea VAUPEL , Nicolas WARIN , Rainer WILCKEN , Lijun XUE , Marie-Anne LOZAC'H , Ross STRANG
IPC: C07D403/14
CPC classification number: C07D403/14
Abstract: Provided are crystalline forms of a KRAS G12C inhibitor compound and to processes for their preparation. Furthermore, provided is pharmaceutical composition comprising said crystalline forms, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition can be used as a medicament, in particular for the treatment of cancer, and KRAS G12C-mutant cancer.
-
公开(公告)号：US20240317721A1
公开(公告)日：2024-09-26
申请号：US18571588
申请日：2022-06-22
Applicant: NOVARTIS AG
Inventor： Claudio BOMIO-CONFAGLIA , Saskia Maria BRACHMANN , Simona COTESTA , Marc GERSPACHER , Catherine LEBLANC , Fabio LIMA , Edwige Liliane Jeanne LORTHIOIS , Rainer MACHAUER , Robert MAH , Sophie RACINE , Pascal RIGOLLIER , Stefan STUTZ , Andrea VAUPEL , Nicolas WARIN , Rainer WILCKEN , Frédéric ZECRI
IPC: C07D403/14 , A61K31/416 , A61K31/4162 , A61K31/437 , A61K31/438 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/4985 , A61K31/499 , A61K31/4995 , A61K31/501 , A61K31/5025 , A61K31/519 , A61K31/5377 , A61K31/5383 , A61K31/5386 , A61K31/541 , A61K31/547 , A61K31/55 , A61K31/551 , A61K31/553 , A61K31/675 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D491/048 , C07D491/107 , C07D495/10 , C07D498/04 , C07D498/08 , C07D498/10 , C07D513/08 , C07F9/6584
CPC classification number: C07D403/14 , A61K31/416 , A61K31/4162 , A61K31/437 , A61K31/438 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/4985 , A61K31/499 , A61K31/4995 , A61K31/501 , A61K31/5025 , A61K31/519 , A61K31/5377 , A61K31/5383 , A61K31/5386 , A61K31/541 , A61K31/547 , A61K31/55 , A61K31/551 , A61K31/553 , A61K31/675 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D491/048 , C07D491/107 , C07D495/10 , C07D498/04 , C07D498/08 , C07D498/10 , C07D513/08 , C07F9/6584
Abstract: The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, and the therapeutic uses of said compound. The present invention further provides a pharmaceutical composition comprising said compound.
-
公开(公告)号：US20140343084A1
公开(公告)日：2014-11-20
申请号：US14327639
申请日：2014-07-10
Applicant: Novartis AG
Inventor： Pascal FURET , Vito GUAGNANO , Philipp HOLZER , Joerg KALLEN , Lv LIAO , Robert MAH , Liang MAO , Keiichi MASUYA , Achim SCHLAPBACH , Stefan STUTZ , Andrea VAUPEL
IPC: C07D487/04
CPC classification number: C07D487/04 , A61K31/4188 , A61K31/4439 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K45/06
Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
Abstract translation: 本发明涉及式（I）化合物：如本文所述，包含这些化合物的药物制剂，用于治疗由MDM2和/或MDM4的活性介导的疾病或疾病的这些化合物的用途和方法，以及 包含这些化合物的组合。
-
Patent Agency Ranking
公开(公告)号：US20190076412A1
公开(公告)日：2019-03-14
申请号：US16190087
申请日：2018-11-13
Applicant: NOVARTIS AG
Inventor： Nicole BUSCHMANN , Robin Alec FAIRHURST , Pascal FURET , Thomas KNÖPFEL , Catherine LEBLANC , Lv LIAO , Robert MAH , Pierre NIMSGERN , Sebastien RIPOCHE , Jing XIONG , Bo HAN , Can WANG , Xianglin ZHAO
IPC: A61K31/4375 , A61K31/4545 , A61P35/00 , A61K31/55 , A61K31/496
Abstract: The present invention relates to therapeutic uses of compounds of formula (1) or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20140011798A1
公开(公告)日：2014-01-09
申请号：US13748790
申请日：2013-01-24
Applicant: NOVARTIS AG
Inventor： Pascal FURET , Vito GUAGNANO , Philipp HOLZER , Joerg KALLEN , Lv LIAO , Robert MAH , Liang MAO , Keiichi MASUYA , Achim SCHLAPBACH , Stefan STUTZ , Andrea VAUPEL
IPC: C07D487/04 , A61K31/4439 , A61K45/06 , A61K31/5377 , A61K31/501 , A61K31/541 , A61K31/4188 , A61K31/506
CPC classification number: C07D487/04 , A61K31/4188 , A61K31/4439 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K45/06
Abstract: The invention relates to compounds of formula (I): as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of MDM2 and/or MDM4, and combinations comprising such compounds.
-
公开(公告)号：US20240366567A1
公开(公告)日：2024-11-07
申请号：US18572518
申请日：2022-06-23
Applicant: NOVARTIS AG
Inventor： Saskia Maria BRACHMANN , Simona COTESTA , Xiaoming CUI , Ruben DE KANTER , Anna FARAGO , Marc GERSPACHER , Diana GRAUS PORTA , Jaeyeon KIM , Catherine LEBLANC , Edwige Liliane Jeanne LORTHIOIS , Rainer MACHAUER , Robert MAH , Christophe MURA , Pascal RIGOLLIER , Anirudh Cadapa PRAHALLAD , Nadine SCHNEIDER , Rowan STRINGER , Stefan STUTZ , Andrea VAUPEL , Nicolas WARIN , Rainer WILCKEN , Andreas WEISS
IPC: A61K31/416 , A61K31/519 , A61K39/00 , A61K45/06 , A61P35/00 , C07K16/22
Abstract: The present invention relates to a pharmaceutical combination comprising a KRAS G12C inhibitor and one or more therapeutic agents which is selected from an agent targeting the MARK pathway or an agent targeting parallel pathways; and pharmaceutical compositions comprising the same. The invention also relates to KRAS G12C inhibitors alone or said combinations for use in methods of treating a cancer or a tumor, in particular wherein the cancer or tumor is KRAS G12C mutant.
-
8.发明公开公开(公告)号：US20240082218A1
公开(公告)日：2024-03-14
申请号：US18267735
申请日：2021-12-20
Applicant: NOVARTIS AG
Inventor： Vasileios ASKOXYLAKIS , Saskia Maria BRACHMANN , Simona COTESTA , Xiaoming CUI , Jeffrey ENGELMAN , Anna FARAGO , Marc GERSPACHER , Diana GRAUS PORTA , Catherine LEBLANC , Edwige Liliane Jeanne LORTHIOIS , Bo LIU , Rainer MACHAUER , Robert MAH , Christophe MURA , Pascal RIGOLLIER , Nadine SCHNEIDER , Stefan STUTZ , Andrea Helga Emmi VAUPEL , Nicolas WARIN , Andreas WEISS , Rainer WILCKEN , Padmaja YERRAMILLI-RAO
IPC: A61K31/416 , A61K9/00 , A61K31/497 , A61K39/395 , A61P35/00
CPC classification number: A61K31/416 , A61K9/0053 , A61K31/497 , A61K39/3955 , A61P35/00
Abstract: It relates to a pharmaceutical combination comprising a KRAS G12C inhibitor, in particular 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro [3.3] heptan-2-yl} prop-2-en-1-one (Compound A) and one or more therapeutically active agents selected from a SHP2 inhibitor (e.g. TNO155) and a PD-1 inhibitor, pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of a cancer or a tumor, in particular wherein the cancer or tumor is KRAS G12C mutated.
-
公开(公告)号：US20180185341A1
公开(公告)日：2018-07-05
申请号：US15516443
申请日：2015-10-02
Applicant: Novartis AG
Inventor： Nicole BUSCHMANN , Robin Alec FAIRHURST , Pascal FURET , Diana GRAUS PORTA , Carolina HAEFLIGER , Bo HAN , Thomas KNÖPFEL , Catherine LEBLANC , Lv LIAO , Robert MAH , Masato MURAKAMI , Pierre NIMSGERN , Michael PALMER , Dale PORTER , Sebastien RIPOCHE , Can WANG , Youzhen WANG , Andreas WEISS , Jing XIONG , Xianglin ZHAO
IPC: A61K31/4375 , A61K31/496 , A61P35/00
CPC classification number: A61K31/4375 , A61K31/4545 , A61K31/496 , A61K31/55 , A61P35/00
Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.017 seconds)
